# To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

> **NCT03081247** · PHASE3 · WITHDRAWN · sponsor: **Pearl Therapeutics, Inc.**

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** BGF 320/14.4/9.6 µg MDI
- **DRUG:** BFF 320/9.6 µg

## Key facts

- **NCT ID:** NCT03081247
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04-16
- **Primary completion:** 2018-12-07
- **Final completion:** 2018-12-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Internal Study team decision not to proceed.
- **Last updated:** 2018-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03081247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03081247, "To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03081247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*